mRNA Synthesis and Manufacturing Market Industry Trends and Global Forecasts to 2035, by Type of Product, Application Area, Therapeutic Area and Key Geographical Regions

The mRNA synthesis and manufacturing market is estimated to be USD 1.15 billion in 2025. It is expected to reach USD 1.35 billion by 2035, representing a CAGR of 20% between 2028 and 2035.

mRNA Synthesis and Manufacturing Market: Growth and Trends

In recent years, mRNA technology has revolutionized the pharmaceutical industry to prevent and treat a wide array of diseases and disorders. The success of COVID-19 vaccines has paved the path for mRNA vaccines and therapeutics. It is worth highlighting that, in the past few years, more than 170 clinical trials related to mRNA-based therapeutics / vaccines have been registered. Multiple preclinical and clinical reports demonstrating the efficacy of these platforms have been published in the last two years. As a result, there is an evident increase in the demand for mRNA manufacturing capacity. However, the synthesis and manufacturing process of mRNA-based therapeutics / vaccines is complex and associated with several challenges.

Production of such drug products requires skilled labor, stringent manufacturing protocols and specialized expertise. Due to such operational and technical challenges associated with the production of RNA-based products, innovators in the biopharmaceutical industry are increasingly relying on contract service providers. In the foreseen future, as more of such RNA-based leads mature and move into the clinic and / or get commercialized, we anticipate the mRNA synthesis and manufacturing services market to witness healthy growth.

mRNA Synthesis and Manufacturing Market: Key Insights

The report delves into the current state of the mRNA synthesis and manufacturing market and identifies potential growth opportunities within the industry.

Some key findings from the report include:

The current market landscape features the presence of more than 35 companies that claim to offer services for custom synthesis of mRNA, across the world.
Various players offer different types of services for mRNA synthesis, based on the requirements of their clients; majority of the players prefer to use plasmid DNA as a starting material to synthesize mRNA.
Over 40 companies currently claim to offer contract manufacturing services for drug substance (mRNA) as well as drug product (mRNA-based vaccines and therapeutics), across various scales of operation.
Several firms (encompassing startups as well as well-established companies), with varying resources, have been actively involved in this domain; the majority of these firms have manufacturing facilities in Europe.
Presently, more than 95 kits (comprising of different components) are available in the market for the synthesis of customized mRNAs; notably, the majority of these have enzymes for cap modification of the mRNA.
mRNA synthesis kits carry out various reactions depending on the number of reagents in the kit; in addition, around 30% of the kits yield over 60 µg of mRNA per reaction.
In pursuit of building a competitive edge, stakeholders are actively upgrading their existing capabilities to enhance their respective service offerings and comply with the evolving industry benchmarks.
In order to meet the rising demand, drug developers are steadily relying on CMOs for the production of mRNA; this approach not only offers a set of streamlined processes but also greater flexibility.
To cater to the rising demand for mRNA synthesis kits, companies are actively undertaking initiatives to integrate advanced features in their respective mRNA synthesis kit portfolios.
Both industry and non-industry players have forged strategic partnerships in the mRNA synthesis and manufacturing domain; notably, majority of the deals in this domain were manufacturing agreements.
Various mRNA-based therapeutic / vaccine developers across the world are anticipated to forge strategic alliances with mRNA synthesis and manufacturing service providers, to further augment their drug portfolio.
Several big pharma players have undertaken a variety of initiatives (partnerships, acquisitions, funding and expansion) for enhancing their mRNA-related portfolio and its therapeutic applicability.
Identifying the driving factors (that fuel advancement) as well as barriers (that slow down research progress) helps improve strategic planning and results in efficient operations in mRNA synthesis and manufacturing domain.
The opportunity within the mRNA synthesis and manufacturing market is likely to be well distributed across different types of product, application area, therapeutic area and key geographical regions.

Report Segmentation

Type of Product

Drug Substances (APIs)
Drug Products (FDFs)

Application Area

mRNA-based Vaccines
mRNA-based Therapeutics

Therapeutic Area

Infectious Diseases
Oncological Disorders
Other Disorders

Key Geographical Regions

North America
Europe
Asia-Pacific
Rest of the World

mRNA Synthesis and Manufacturing Market: Key Segments

Drug Substances (APIs) are Likely to Dominate the mRNA Synthesis and Manufacturing Market During the Forecast Period

Based on type of product, the market is segmented into drug substances (APIs) and drug products (FDFs). It is worth highlighting that majority of the current mRNA synthesis and manufacturing market is captured by bulk drug substances (APIs) and this trend is likely to remain the same in near future.

mRNA Therapeutics is the Fastest Growing Segment in the mRNA Synthesis and Manufacturing Market During the Forecast Period

Based on application area, the market is segmented into mRNA-based vaccines and mRNA-based therapeutics. It is worth highlighting that that majority of the current mRNA synthesis and manufacturing market is captured by mRNA vaccines.

Infectious Diseases Segment Accounts for the Largest Share for the mRNA Synthesis and Manufacturing Market

Based on therapeutic area, the market is segmented into infectious diseases, oncological disorders and other disorders. While infectious diseases account for a relatively higher market share, it is worth highlighting that oncological disorders segment is expected to witness substantial market growth in the coming years.

North America Holds the Largest Share of the Market

Based on key geographical regions, the market is segmented into North America, Europe, Asia-Pacific and Rest of the World. It is worth highlighting that currently, North America captures majority of the mRNA synthesis and manufacturing market, and this trend is unlikely to change in the near future.

Sample Players in the mRNA Synthesis and Manufacturing Market, Profiled in the Report Include:

Aldevron
Aurigene Pharmaceutical Services
Biomay
Curia
eTheRNA
Eurogentec
Genscript
Merck KGaA
TriLink BioTechnologies
Vernal Biosciences
WuXi Biologics
APExBIO
CELLSCRIPT
Enzynomics
Jena Bioscience
New England Biolabs
Thermo Fisher Scientific

Primary Research Overview

The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders. The research report features detailed transcripts of interviews held with the following industry stakeholders:

Chief Executive Officer, eTheRNA
Chief Commercial Officer, tebubio
Business Development Manager, Canvax
Team Leader, GC Pharma

mRNA Synthesis and Manufacturing Market: Research Coverage

The report features an in-depth analysis of the mRNA synthesis and manufacturing market, focusing on key market segments, including type of product, application area, therapeutic area and key geographical regions.
The report analyzes various factors such as drivers, restraints, opportunities, and challenges affecting the market growth.
A comprehensive evaluation of mRNA custom synthesis service providers, considering various parameters, such as year of establishment, company size (in terms of number of employees), location of headquarters (North America, Europe and Asia Pacific), type of services offered (mRNA modification, mRNA purification, scale-up, process development and fill / finish), starting material (plasmid DNA, mRNA sequence and PCR fragments), structural modification (5’ modification, 3’ modification, ribonucleotide base modification and others), type of purification method (chromatography, electrophoresis, desalting / precipitation and others), application area (vaccine production, therapeutic production and others) and scale of operation (preclinical / research, clinical and commercial). Further, the chapter also features information on the length of the mRNA manufactured and mRNA production capacity of the stakeholders.
A comprehensive competitive analysis of mRNA custom synthesis service providers (across key geographical regions), examining factors such as supplier strength and service strength.
Thorough analysis of mRNA contract manufacturing service providers, detailing year of establishment, company size (in terms of number of employees), location of headquarters (North America, Europe and Asia Pacific), location of manufacturing facilities, type of additional services offered (formulation development, analytical testing, process development, mRNA purification, fill / finish, scale-up, regulatory support and others) type of product manufactured (drug substances (APIs) and drug products (FDFs)) and scale of operation (preclinical / research, clinical and commercial).
A comprehensive competitive analysis of mRNA contract manufacturing service providers (across key geographical regions), examining factors such as supplier strength and service portfolio strength.
A detailed assessment of the current market landscape of mRNA synthesis kits based on several relevant parameters, such as kit components (enzyme mix, reagents, buffer and others), type of enzyme (capping enzyme and tailing enzyme), type of enzyme mix used (T7 polymerase, SP6 polymerase and T3 polymerase), mRNA component modified (cap, base and tail), number of reactions (5 reactions, 10 reactions, 15 reactions, 16 reactions, 20 reactions, 25 reactions, 48 reactions and 50 reactions), yield per reaction (less than 31µg, 31-60 µg, 61-90 µg and more than 90 µg), reaction run time (less than 61 minutes, 61-120 minutes and more than 120 minutes) and kit price (less than USD 500, USD 501-USD 700, USD 701-USD 900 USD, USD 901-USD 1,200 and more than 1,200 USD). In addition, the chapter provides a detailed analysis of mRNA synthesis kit providers, along with information on their year of establishment, company size (in terms of employees count), location of headquarters and most active players (in terms of number of mRNA synthesis kits offered).
An insightful analysis of mRNA synthesis kits, based on supplier strength and product strength.
In-depth profiles of key industry players in mRNA manufacturing market, focusing on company overviews, service portfolio, recent developments and an informed future outlook.
Detailed profiles of the key mRNA synthesis kit providers, focusing on company overviews and mRNA synthesis kits portfolio.
An analysis of partnerships established in this sector, since 2019, on the basis of several parameters, such as year of partnership, type of product, type of partner and most active players (in terms of the number of partnerships signed). It also provides for the regional distribution of the companies involved in these agreements.
A detailed evaluation of over 35 mRNA-based therapeutics / vaccines developers that are most likely to collaborate with mRNA contract manufacturing service providers. This analysis considers various relevant parameters, including developer strength (in terms of company’s experience), company size, (in terms of number of employees), pipeline strength (based on the number of mRNA-based drugs in pipeline), highest phase of development, therapeutic area, route of administration and type of candidate being developed.
Assessment of the various mRNA-focused initiatives undertaken by big pharma players, based on several relevant parameters, such as number of initiatives, year of initiative, purpose of initiative, type of initiative and therapeutic area.

Key Questions Answered in this Report

How many companies are currently engaged in this market?
Which are the leading companies in this market?
What kind of partnership models are commonly adopted by industry stakeholders?
What are the factors that are likely to influence the evolution of this market?
What is current and future market size?
What is the CAGR of this market?
How is the current and future market opportunity likely to be distributed across key market segments?

Reasons to Buy this Report

The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

Additional Benefits

Complimentary PPT Insights Packs
Complimentary Excel Data Packs for all Analytical Modules in the Report
10% Free Content Customization
Detailed Report Walkthrough Session with Research Team
Free Updated report if the report is 6-12 months old or older

1. BACKGROUND

1.1. Context
1.2. Project Objectives

2. RESEARCH METHODOLOGY

2.1. Chapter Overview
2.2. Research Assumptions
2.2.1. Market Landscape and Market Trends
2.2.2. Market Forecast and Opportunity Analysis
2.2.3. Comparative Analysis
2.3. Database Building
2.3.1. Data Collection
2.3.2. Data Validation
2.3.3. Data Analysis
2.4. Project Methodology
2.4.1. Secondary Research
2.4.1.1. Annual Reports
2.4.1.2. Academic Research Papers
2.4.1.3. Company Websites
2.4.1.4. Investor Presentations
2.4.1.5. Regulatory Filings
2.4.1.6. White Papers
2.4.1.7. Industry Publications
2.4.1.8. Conferences and Seminars
2.4.1.9. Government Portals
2.4.1.10. Media and Press Releases
2.4.1.11. Newsletters
2.4.1.12. Industry Databases
2.4.1.13. Roots Proprietary Databases
2.4.1.14. Paid Databases and Sources
2.4.1.15. Social Media Portals
2.4.1.16. Other Secondary Sources
2.4.2. Primary Research
2.4.2.1. Types of Primary Research
2.4.2.1.1. Qualitative Research
2.4.2.1.2. Quantitative Research
2.4.2.1.3. Hybrid Approach
2.4.2.2. Advantages of Primary Research
2.4.2.3. Techniques for Primary Research
2.4.2.3.1. Interviews
2.4.2.3.2. Surveys
2.4.2.3.3. Focus Groups
2.4.2.3.4. Observational Research
2.4.2.3.5. Social Media Interactions
2.4.2.4. Key Opinion Leaders Considered in Primary Research
2.4.2.4.1. Company Executives (CXOs)
2.4.2.4.2. Board of Directors
2.4.2.4.3. Company Presidents and Vice Presidents
2.4.2.4.4. Research and Development Heads
2.4.2.4.5. Technical Experts
2.4.2.4.6. Subject Matter Experts
2.4.2.4.7. Scientists
2.4.2.4.8. Doctors and Other Healthcare Providers
2.4.2.5. Ethics and Integrity
2.4.2.5.1. Research Ethics
2.4.2.5.2. Data Integrity
2.4.3. Analytical Tools and Databases
2.5. Robust Quality Control

3. MARKET DYNAMICS

3.1. Chapter Overview
3.2. Forecast Methodology
3.2.1. Top-down Approach
3.2.2. Bottom-up Approach
3.2.3. Hybrid Approach
3.3. Market Assessment Framework
3.3.1. Total Addressable Market (TAM)
3.3.2. Serviceable Addressable Market (SAM)
3.3.3. Serviceable Obtainable Market (SOM)
3.3.4. Currently Acquired Market (CAM)
3.4. Forecasting Tools and Techniques
3.4.1. Qualitative Forecasting
3.4.2. Correlation
3.4.3. Regression
3.4.4. Extrapolation
3.4.5. Convergence
3.4.6. Sensitivity Analysis
3.4.7. Scenario Planning
3.4.8. Data Visualization
3.4.9. Time Series Analysis
3.4.10. Forecast Error Analysis
3.5. Key Considerations
3.5.1. Demographics
3.5.2. Government Regulations
3.5.3. Reimbursement Scenarios
3.5.4. Market Access
3.5.5. Supply Chain
3.5.6. Industry Consolidation
3.5.7. Pandemic / Unforeseen Disruptions Impact
3.6. Limitations

4. MACRO-ECONOMIC INDICATORS

4.1. Chapter Overview
4.2. Market Dynamics
4.2.1. Time Period
4.2.1.1. Historical Trends
4.2.1.2. Current and Forecasted Estimates
4.2.2. Currency Coverage
4.2.2.1. Major Currencies Affecting the Market
4.2.2.2. Factors Affecting Currency Fluctuations on the Industry
4.2.2.3. Impact of Currency Fluctuations on the Industry
4.2.3. Foreign Currency Exchange Rate
4.2.3.1. Impact of Foreign Exchange Rate Volatility on the Market
4.2.3.2. Strategies for Mitigating Foreign Exchange Risk
4.2.4. Recession
4.2.4.1. Assessment of Current Economic Conditions and Potential Impact on the Market
4.2.4.2. Historical Analysis of Past Recessions and Lessons Learnt
4.2.5. Inflation
4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
4.2.5.2. Potential Impact of Inflation on the Market Evolution
4.2.6. Interest Rates
4.2.6.1. Interest Rates and Their Impact on the Market
4.2.6.2. Strategies for Managing Interest Rate Risk
4.2.7. Commodity Flow Analysis
4.2.7.1. Type of Commodity
4.2.7.2. Origins and Destinations
4.2.7.3. Values and Weights
4.2.7.4. Modes of Transportation
4.2.8. Global Trade Dynamics
4.2.8.1. Import Scenario
4.2.8.2. Export Scenario
4.2.8.3. Trade Policies
4.2.8.4. Strategies for Mitigating the Risks Associated with Trade Barriers
4.2.8.5. Impact of Trade Barriers on the Market
4.2.9. War Impact Analysis
4.2.9.1. Russian-Ukraine War
4.2.9.2. Israel-Hamas War
4.2.10. COVID Impact / Related Factors
4.2.10.1. Global Economic Impact
4.2.10.2. Industry-specific Impact
4.2.10.3. Government Response and Stimulus Measures
4.2.10.4. Future Outlook and Adaptation Strategies
4.2.11. Other Indicators
4.2.11.1. Fiscal Policy
4.2.11.2. Consumer Spending
4.2.11.3. Gross Domestic Product
4.2.11.4. Employment
4.2.11.5. Taxes
4.2.11.6. Stock Market Performance
4.2.11.7. Cross Border Dynamics
4.3. Conclusion

5. EXECUTIVE SUMMARY

5.1. Executive Summary: Market Landscape
5.2. Executive Summary: Market Trends
5.3. Executive Summary: Market Forecast and Opportunity Analysis

6. INTRODUCTION

6.1. Overview of mRNA
6.2. Structure of mRNA
6.3. Evolution of mRNA Vaccines
6.4. Types of mRNA Synthesis Processes
6.4.1. Chemical Synthesis of mRNA
6.4.2. In vitro Synthesis of mRNA
6.5. Applications of mRNA
6.6. Challenges Associated with mRNA Synthesis
6.7. Commonly Outsourced mRNA Manufacturing Operations
6.8. Advantages of Outsourcing Manufacturing Operations
6.9. Conclusion

7. mRNA CUSTOM SYNTHESIS SERVICE PROVIDERS: MARKET LANDSCAPE

7.1. Overview of mRNA Custom Synthesis Service Providers
7.1.1. Analysis by Year of Establishment
7.1.2. Analysis by Company Size
7.1.3. Analysis by Location of Headquarters
7.1.4. Analysis by Company Size and Location of Headquarters
7.1.5. Analysis by Type of Service Offered
7.1.6. Analysis by Type of Starting Material
7.1.7. Analysis by Structural Modification
7.1.8. Analysis by Type of Purification Method
7.1.9. Analysis by Scale of Operation
7.1.10. Analysis by Application Area
7.1.11. Analysis by GMP Compliance

8. COMPANY COMPETITVENESS ANALYSIS: mRNA CUSTOM SYNTHESIS SERVICE PROVIDERS

8.1. Methodology and Key Parameters
8.2. Scoring Criteria
8.3. Overview of Peer Groups
8.4. Company Competitiveness Analysis
8.4.1. Competitiveness Analysis of Service Providers headquartered in North America: 2D Dot Plot
8.4.2. Leading Service Providers headquartered in North America: Spider Web Analysis
8.4.3. Competitiveness Analysis of Service Providers headquartered in Europe: 2D Dot Plot
8.4.4. Leading Service Providers headquartered in Europe: Spider Web Analysis
8.4.5. Competitiveness Analysis of Service Providers headquartered in Asia-Pacific: 2D Dot Plot
8.4.6. Leading Service Providers headquartered in Asia-Pacific: Spider Web Analysis

9. mRNA CONTRACT MANUFACTURING SERVICE PROVIDERS: MARKET LANDSCAPE

9.1. Overview of mRNA Contract Manufacturing Service Providers
9.1.1. Analysis by Year of Establishment
9.1.2. Analysis by Company Size
9.1.3. Analysis by Location of Headquarters (Region)
9.1.4. Analysis by Location of Headquarters (Country)
9.1.5. Analysis by Location of Manufacturing Facilities
9.1.6. Analysis by Type of Product Manufactured
9.1.7. Analysis by GMP Compliance
9.1.8. Analysis by Scale of Operation
9.1.9. Analysis by Type of Additional Services Offered

10. COMPANY COMPETITVENESS ANALYSIS: mRNA CONTRACT MANUFACTURING SERVICE PROVIDERS

10.1. Methodology and Key Parameters
10.2. Scoring Criteria
10.3. Overview of Peer Groups
10.4. Company Competitiveness Analysis
10.4.1. Competitiveness Analysis of Service Providers headquartered in North America: 2D Dot Plot
10.4.2. Leading Service Providers headquartered in North America: Spider Web Analysis
10.4.3. Competitiveness Analysis of Service Providers headquartered in Europe: 2D Dot Plot
10.4.4. Leading Service Providers headquartered in Europe: Spider Web Analysis
10.4.5. Competitiveness Analysis of Service Providers headquartered in Asia-Pacific: 2D Dot Plot
10.4.6. Leading Service Providers headquartered in Asia-Pacific: Spider Web Analysis

11. mRNA SYNTHESIS KITS: MARKET LANDSCAPE

11.1. Overview of mRNA Synthesis Kits
11.1.1. Analysis by Kit Components
11.1.2. Analysis by Type of Enzyme
11.1.3. Analysis by Type of Enzyme Mix Used
11.1.4. Analysis by mRNA Component Modified
11.1.5. Analysis by Number of Reactions
11.1.6. Analysis by Yield per Reaction
11.1.7. Analysis by Reaction Run-time
11.1.8. Analysis by Shelf Life
11.2. mRNA Synthesis Kits: Developers Landscape
11.2.1. Analysis by Year of Establishment
11.2.2. Analysis by Company Size
11.2.3. Analysis by Location of Headquarters
11.2.4. Most Active Players: Analysis by Number of Kits Developed

12. PRODUCT COMPETITVENESS ANALYSIS: mRNA SYNTHESIS KITS

12.1. Methodology and Key Parameters
12.2. Scoring Criteria
12.3. Leading mRNA Synthesis Kits: 2D Dot Plot

13. COMPANY PROFILES: mRNA CUSTOM SYNTHESIS SERVICE PROVIDERS

13.1. Methodology
13.2. Aldevron
13.2.1. Company Details
13.2.2. Service Portfolio
13.2.3. Financial Information
13.2.4. Future Outlook
13.3. Thermo Fischer Scientific
13.4. Revolution Biomanufacturing
13.5. BioNTech
13.6. Eurogentec
13.7. Biocell
13.8. YXgene
13.9. Aurigene Pharmaceutical Services
13.10. Biomay
13.11. GenScript
13.12. Trilink Biotechnologies

14. COMPANY PROFILES: mRNA CONTRACT MANUFACTURING SERVICE PROVIDERS

14.1. Methodology
14.2. Curia
14.2.1. Company Details
14.2.2. Service Portfolio
14.2.3. Financial Information
14.2.4. Future Outlook
14.3. Lonza
14.4. Merck
14.5. Porton Advanced
14.6. Samsung Biologics
14.7. ST Pharm
14.8. Vernal Biosciences
14.9. Wuxi Biologics

15. COMPANY PROFILES: mRNA SYNTHESIS KITS

15.1. Methodology
15.2. APExBIO
15.2.1. Company Details
15.2.2. mRNA Synthesis Kits Portfolio
15.3. Biorbyt
15.4. Cell Script
15.5. Creative Biogene
15.6. Jena Bioscience
15.7. Thermo Fischer Scientific

16. PARTNERSHIPS AND COLLABORATIONS

16.1. Partnership Models
16.2. mRNA Synthesis and Manufacturing Market: Partnerships and Collaborations
16.2.1. Analysis by Year of Partnership
16.2.2. Analysis by Type of Partnership
16.2.3. Analysis by Year and Type of Partnership
16.2.4. Analysis by Type of Partner
16.2.5. Analysis by Type of Pharmaceutical
16.2.6. Analysis by Type of Drug Product
16.2.7. Most Active Players: Analysis by Number of Partnerships
16.2.8. Analysis by Geography
16.2.8.1. Local and International Deals
16.2.8.2. Intracontinental and Intercontinental Deals

17. LIKELY PARTNER ANALYSIS

17.1. mRNA Synthesis and Manufacturing Market: Likely Partner Analysis
17.2. Methodology and Key Parameters
17.3. Scoring Criteria
17.4. mRNA Drug Developers: Likely Partners based in North America
17.4.1. mRNA Drug Developers: Most Likely Partners based in North America
17.5. mRNA Drug Developers: Likely Partners based in Europe
17.5.1. mRNA Drug Developers: Most Likely Partners based in Europe
17.6. mRNA Drug Developers: Likely Partners based in Asia-Pacific and Rest of the World
17.6.1. mRNA Drug Developers: Most Likely Partners based in Asia-Pacific and Rest of the World

18. BIG PLAYER INITIATIVES

18.1. Methodology
18.2. Key Initiatives Analyzed
18.3. mRNA Synthesis and Manufacturing Market: Big Player Initiatives
18.3.1. Analysis by Year of Initiative
18.3.2. Analysis by Type of Initiative
18.3.3. Analysis by Year and Type of Initiative
18.3.4. Big Players: Analysis by Number of Initiatives
18.3.5. Big Players: Analysis by Type of Initiative
18.3.6. Analysis by Type of Pharmaceutical
18.3.7. Analysis by Therapeutic Area
18.3.8. Big Players: Analysis by Number of Partnerships
18.3.9. Analysis by Type of Partnership
18.3.10. Big Players: Analysis by Number of Expansions
18.3.11. Analysis by Type of Expansion
18.3.12. Big Players: Analysis by Region of Expansion

19. MARKET IMPACT ANALYSIS

19.1. Market Drivers
19.2. Market Restraints
19.3. Market Opportunities
19.4. Market Challenges

20. GLOBAL mRNA SYNTHESIS AND MANUFACTURING MARKET

20.1. Key Assumptions and Methodology
20.2. Global mRNA Synthesis and Manufacturing Market: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
20.2.1. Scenario Analysis
20.2.1.1. Conservative Scenario
20.2.1.2. Optimistic Scenario
20.3. Comparison with Previous Edition
20.4. Key Market Segmentations

21. mRNA SYNTHESIS AND MANUFACTURING MARKET, BY TYPE OF PRODUCT

21.1. Methodology
21.2. mRNA Synthesis and Manufacturing Market: Distribution by Type of Product
21.2.1. mRNA Synthesis and Manufacturing Market for Active Pharmaceutical Ingredients: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
21.2.2. mRNA Synthesis and Manufacturing Market for Finished Dose Formulations: Historical Trends (since 2021) and Forecasted Estimates (till 2035)

22. mRNA SYNTHESIS AND MANUFACTURING MARKET, BY SCALE OF OPERATION

22.1. Methodology
22.2. mRNA Synthesis and Manufacturing Market: Distribution by Scale of Operation
22.2.1. mRNA Synthesis and Manufacturing Market for Preclinical and Clinical Scale: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
22.2.2. mRNA Synthesis and Manufacturing Market for Commercial Scale: Historical Trends (since 2021) and Forecasted Estimates (till 2035)

23. mRNA SYNTHESIS AND MANUFACTURING MARKET, BY SYNTHESIS AND MANUFACTURING ACTIVITY

23.1. Methodology
23.2. mRNA Synthesis and Manufacturing Market: Distribution by Synthesis and Manufacturing Activity
23.2.1. mRNA Synthesis and Manufacturing Market for Contract Manufacturing: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
23.2.2. mRNA Synthesis and Manufacturing Market for In-house Manufacturing: Historical Trends (since 2021) and Forecasted Estimates (till 2035)

24. mRNA SYNTHESIS AND MANUFACTURING MARKET, BY INDICATION TYPE

24.1. Methodology
24.2. mRNA Synthesis and Manufacturing Market: Distribution by Indication Type
24.2.1. mRNA Synthesis and Manufacturing Market for COVID Indications: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
24.2.2. mRNA Synthesis and Manufacturing Market for Non-COVID Indications: Historical Trends (since 2021) and Forecasted Estimates (till 2035)

25. mRNA SYNTHESIS AND MANUFACTURING MARKET, BY THERAPEUTIC AREA

25.1. Methodology
25.2. mRNA Synthesis and Manufacturing Market: Distribution by Therapeutic Area
25.2.1. mRNA Synthesis and Manufacturing Market for Infectious Diseases: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
25.2.2. mRNA Synthesis and Manufacturing Market for Oncological Disorders: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
25.2.3. mRNA Synthesis and Manufacturing Market for Other Disorders: Historical Trends (since 2021) and Forecasted Estimates (till 2035)

26. mRNA SYNTHESIS AND MANUFACTURING MARKET, BY APPLICATION AREA

26.1. Methodology
26.2. mRNA Synthesis and Manufacturing Market: Distribution by Application Area
26.2.1. mRNA Synthesis and Manufacturing Market for mRNA Vaccines: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
26.2.2. mRNA Synthesis and Manufacturing Market for mRNA Therapeutics: Historical Trends (since 2021) and Forecasted Estimates (till 2035)

27. mRNA SYNTHESIS AND MANUFACTURING MARKET, BY GEOGRAPHICAL REGIONS

27.1. Methodology
27.2. mRNA Synthesis and Manufacturing Market: Distribution by Geographical Regions
27.2.1. mRNA Synthesis and Manufacturing Market in North America: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
27.2.1.1. mRNA Synthesis and Manufacturing Market in the US: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
27.2.1.2. mRNA Synthesis and Manufacturing Market in Canada: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
27.2.2. mRNA Synthesis and Manufacturing Market in Europe: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
27.2.2.1. mRNA Synthesis and Manufacturing Market in Germany: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
27.2.2.2. mRNA Synthesis and Manufacturing Market in France: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
27.2.2.3. mRNA Synthesis and Manufacturing Market in the UK: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
27.2.2.4. mRNA Synthesis and Manufacturing Market in Italy: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
27.2.2.5. mRNA Synthesis and Manufacturing Market in Spain: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
27.2.2.6. mRNA Synthesis and Manufacturing Market in Rest of Europe: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
27.2.3. mRNA Synthesis and Manufacturing Market in Asia-Pacific: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
27.2.3.1. mRNA Synthesis and Manufacturing Market in China: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
27.2.3.2. mRNA Synthesis and Manufacturing Market in India: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
27.2.3.3. mRNA Synthesis and Manufacturing Market in Japan: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
27.2.3.4. mRNA Synthesis and Manufacturing Market in South Korea: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
27.2.3.5. mRNA Synthesis and Manufacturing Market in Rest of Asia-Pacific: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
27.2.4. mRNA Synthesis and Manufacturing Market in Latin America: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
27.2.4.1. mRNA Synthesis and Manufacturing Market in Brazil: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
27.2.4.2. mRNA Synthesis and Manufacturing Market in Argentina: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
27.2.5. mRNA Synthesis and Manufacturing Market in Middle East and North Africa: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
27.2.5.1. mRNA Synthesis and Manufacturing Market in Saudi Arabia: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
27.2.5.2. mRNA Synthesis and Manufacturing Market in Israel: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
27.2.5.3. mRNA Synthesis and Manufacturing Market in United Arab Emirates: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
27.2.5.4. mRNA Synthesis and Manufacturing Market in Rest of Middle East and North Africa: Historical Trends (since 2021) and Forecasted Estimates (till 2035)

28. MARKET OPPORTUNITY ANALYSIS: NORTH AMERICA

28.1. mRNA Synthesis and Manufacturing Market in North America: Distribution by Type of Product
28.1.1. mRNA Synthesis and Manufacturing Market in North America for Active Pharmaceutical Ingredient, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
28.1.2. mRNA Synthesis and Manufacturing Market in North America for Finished Dose Formulation, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
28.2. mRNA Synthesis and Manufacturing Market in North America: Distribution by Scale of Operation
28.2.1. mRNA Synthesis and Manufacturing Market in North America for Preclinical and Clinical Scale, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
28.2.2. mRNA Synthesis and Manufacturing Market in North America for Commercial Scale, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
28.3. mRNA Synthesis and Manufacturing Market in North America: Distribution by Synthesis and Manufacturing Activity
28.3.1. mRNA Synthesis and Manufacturing Market in North America for Contract Manufacturing, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
28.3.2. mRNA Synthesis and Manufacturing Market in North America for In-house Manufacturing, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
28.4. mRNA Synthesis and Manufacturing Market in North America: Distribution by Indication Type
28.4.1. mRNA Synthesis and Manufacturing Market in North America for COVID Indications, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
28.4.2. mRNA Synthesis and Manufacturing Market in North America for non-COVID Indications, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
28.5. mRNA Synthesis and Manufacturing Market in North America: Distribution by Therapeutic Area
28.5.1. mRNA Synthesis and Manufacturing Market in North America for Infectious Diseases, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
28.5.2. mRNA Synthesis and Manufacturing Market in North America for Oncological Disorders, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
28.5.3. mRNA Synthesis and Manufacturing Market in North America for Other Disorders, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
28.6. mRNA Synthesis and Manufacturing Market in North America: Distribution by Application Area
28.6.1. mRNA Synthesis and Manufacturing Market in North America for mRNA Vaccines, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
28.6.2. mRNA Synthesis and Manufacturing Market in North America for mRNA Therapeutics, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

29. MARKET OPPORTUNITY ANALYSIS: EUROPE

29.1. mRNA Synthesis and Manufacturing Market in Europe: Distribution by Type of Product
29.1.1. mRNA Synthesis and Manufacturing Market in Europe for Active Pharmaceutical Ingredient, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
29.1.2. mRNA Synthesis and Manufacturing Market in Europe for Finished Dose Formulation, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
29.2. mRNA Synthesis and Manufacturing Market in Europe: Distribution by Scale of Operation
29.2.1. mRNA Synthesis and Manufacturing Market in Europe for Preclinical and Clinical Scale, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
29.2.2. mRNA Synthesis and Manufacturing Market in Europe for Commercial Scale, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
29.3. mRNA Synthesis and Manufacturing Market in Europe: Distribution by Synthesis and Manufacturing Activity
29.3.1. mRNA Synthesis and Manufacturing Market in Europe for Contract Manufacturing, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
29.3.2. mRNA Synthesis and Manufacturing Market in Europe for In-house Manufacturing, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
29.4. mRNA Synthesis and Manufacturing Market in Europe: Distribution by Indication Type
29.4.1. mRNA Synthesis and Manufacturing Market in Europe for COVID Indications, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
29.4.2. mRNA Synthesis and Manufacturing Market in Europe for non-COVID Indications, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
29.5. mRNA Synthesis and Manufacturing Market in Europe: Distribution by Therapeutic Area
29.5.1. mRNA Synthesis and Manufacturing Market in Europe for Infectious Diseases, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
29.5.2. mRNA Synthesis and Manufacturing Market in Europe for Oncological Disorders, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
29.5.3. mRNA Synthesis and Manufacturing Market in Europe for Other Disorders, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
29.6. mRNA Synthesis and Manufacturing Market in Europe: Distribution by Application Area
29.6.1. mRNA Synthesis and Manufacturing Market in Europe for mRNA Vaccines, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
29.6.2. mRNA Synthesis and Manufacturing Market in Europe for mRNA Therapeutics, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

30. MARKET OPPORTUNITY ANALYSIS: ASIA-PACIFIC

30.1. mRNA Synthesis and Manufacturing Market in Asia-Pacific: Distribution by Type of Product
30.1.1. mRNA Synthesis and Manufacturing Market in Asia-Pacific for Active Pharmaceutical Ingredient, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
30.1.2. mRNA Synthesis and Manufacturing Market in Asia-Pacific for Finished Dose Formulation, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
30.2. mRNA Synthesis and Manufacturing Market in Asia-Pacific: Distribution by Scale of Operation
30.2.1. mRNA Synthesis and Manufacturing Market in Asia-Pacific for Preclinical and Clinical Scale, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
30.2.2. mRNA Synthesis and Manufacturing Market in Asia-Pacific for Commercial Scale, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
30.3. mRNA Synthesis and Manufacturing Market in Asia-Pacific: Distribution by Synthesis and Manufacturing Activity
30.3.1. mRNA Synthesis and Manufacturing Market in Asia-Pacific for Contract Manufacturing, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
30.3.2. mRNA Synthesis and Manufacturing Market in Asia-Pacific for In-house Manufacturing, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
30.4. mRNA Synthesis and Manufacturing Market in Asia-Pacific: Distribution by Indication Type
30.4.1. mRNA Synthesis and Manufacturing Market in Asia-Pacific for COVID Indications, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
30.4.2. mRNA Synthesis and Manufacturing Market in Asia-Pacific for non-COVID Indications, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
30.5. mRNA Synthesis and Manufacturing Market in Asia-Pacific: Distribution by Therapeutic Area
30.5.1. mRNA Synthesis and Manufacturing Market in Asia-Pacific for Infectious Diseases, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
30.5.2. mRNA Synthesis and Manufacturing Market in Asia-Pacific for Oncological Disorders, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
30.5.3. mRNA Synthesis and Manufacturing Market in Asia-Pacific for Other Disorders, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
30.6. mRNA Synthesis and Manufacturing Market in Asia-Pacific: Distribution by Application Area
30.6.1. mRNA Synthesis and Manufacturing Market in Asia-Pacific for mRNA Vaccines, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
30.6.2. mRNA Synthesis and Manufacturing Market in Asia-Pacific for mRNA Therapeutics, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

31. MARKET OPPORTUNITY ANALYSIS: LATIN AMERICA

31.1. mRNA Synthesis and Manufacturing Market in Latin America: Distribution by Type of Product
31.1.1. mRNA Synthesis and Manufacturing Market in Latin America for Active Pharmaceutical Ingredient, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
31.1.2. mRNA Synthesis and Manufacturing Market in Latin America for Finished Dose Formulation, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
31.2. mRNA Synthesis and Manufacturing Market in Latin America: Distribution by Scale of Operation
31.2.1. mRNA Synthesis and Manufacturing Market in Latin America for Preclinical and Clinical Scale, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
31.2.2. mRNA Synthesis and Manufacturing Market in Latin America for Commercial Scale, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
31.3. mRNA Synthesis and Manufacturing Market in Latin America: Distribution by Synthesis and Manufacturing Activity
31.3.1. mRNA Synthesis and Manufacturing Market in Latin America for Contract Manufacturing, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
31.3.2. mRNA Synthesis and Manufacturing Market in Latin America for In-house Manufacturing, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
31.4. mRNA Synthesis and Manufacturing Market in Latin America: Distribution by Indication Type
31.4.1. mRNA Synthesis and Manufacturing Market in Latin America for COVID Indications, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
31.4.2. mRNA Synthesis and Manufacturing Market in Latin America for non-COVID Indications, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
31.5. mRNA Synthesis and Manufacturing Market in Latin America: Distribution by Therapeutic Area
31.5.1. mRNA Synthesis and Manufacturing Market in Latin America for Infectious Diseases, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
31.5.2. mRNA Synthesis and Manufacturing Market in Latin America for Oncological Disorders, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
31.5.3. mRNA Synthesis and Manufacturing Market in Latin America for Other Disorders, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
31.6. mRNA Synthesis and Manufacturing Market in Latin America: Distribution by Application Area
31.6.1. mRNA Synthesis and Manufacturing Market in Latin America for mRNA Vaccines, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
31.6.2. mRNA Synthesis and Manufacturing Market in Latin America for mRNA Therapeutics, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

32. MARKET OPPORTUNITY ANALYSIS: MIDDLE EAST AND NORTH AFRICA

32.1. mRNA Synthesis and Manufacturing Market in Middle East and North Africa: Distribution by Type of Product
32.1.1. mRNA Synthesis and Manufacturing Market in Middle East and North Africa for Active Pharmaceutical Ingredient, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
32.1.2. mRNA Synthesis and Manufacturing Market in Middle East and North Africa for Finished Dose Formulation, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
32.2. mRNA Synthesis and Manufacturing Market in Middle East and North Africa: Distribution by Scale of Operation
32.2.1. mRNA Synthesis and Manufacturing Market in Middle East and North Africa for Preclinical and Clinical Scale, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
32.2.2. mRNA Synthesis and Manufacturing Market in Middle East and North Africa for Commercial Scale, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
32.3. mRNA Synthesis and Manufacturing Market in Middle East and North Africa: Distribution by Synthesis and Manufacturing Activity
32.3.1. mRNA Synthesis and Manufacturing Market in Middle East and North Africa for Contract Manufacturing, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
32.3.2. mRNA Synthesis and Manufacturing Market in Middle East and North Africa for In-house Manufacturing, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
32.4. mRNA Synthesis and Manufacturing Market in Middle East and North Africa: Distribution by Indication Type
32.4.1. mRNA Synthesis and Manufacturing Market in Middle East and North Africa for COVID Indications, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
32.4.2. mRNA Synthesis and Manufacturing Market in Middle East and North Africa for non-COVID Indications, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
32.5. mRNA Synthesis and Manufacturing Market in Middle East and North Africa: Distribution by Therapeutic Area
32.5.1. mRNA Synthesis and Manufacturing Market in Middle East and North Africa for Infectious Diseases, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
32.5.2. mRNA Synthesis and Manufacturing Market in Middle East and North Africa for Oncological Disorders, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
32.5.3. mRNA Synthesis and Manufacturing Market in Middle East and North Africa for Other Disorders, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
32.6. mRNA Synthesis and Manufacturing Market in Middle East and North Africa: Distribution by Application Area
32.6.1. mRNA Synthesis and Manufacturing Market in Middle East and North Africa for mRNA Vaccines, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
32.6.2. mRNA Synthesis and Manufacturing Market in Middle East and North Africa for mRNA Therapeutics, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

33. CONCLUDING INSIGHTS34. EXECUTIVE INSIGHTS35. APPENDIX I: TABULATED DATA36. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

LIST OF FIGURES

Figure 2.1 Research Methodology: Project Methodology
Figure 2.2 Research Methodology: Data Sources for Secondary Research
Figure 2.3 Research Methodology: Robust Quality Control
Figure 3.1 Market Dynamics: Forecast Methodology
Figure 3.2 Market Dynamics: Market Assessment Framework
Figure 4.1 Lessons Learnt from Past Recessions
Figure 5.1 Executive Summary: Market Landscape
Figure 5.2 Executive Summary: Market Trends
Figure 5.3 Executive Summary: Market Forecast and Opportunity Analysis
Figure 6.1 Structure of mRNA
Figure 6.2 Evolution of mRNA Vaccines
Figure 6.3 Chemical Synthesis
Figure 6.4 In-vitro Synthesis
Figure 6.5 Applications of mRNA
Figure 6.6 Advantages of Outsourcing Manufacturing Operations
Figure 7.1 mRNA Custom Synthesis Service Providers: Distribution by Year of Establishment
Figure 7.2 mRNA Custom Synthesis Service Providers: Distribution by Company Size
Figure 7.3 mRNA Custom Synthesis Service Providers: Distribution by Location of Headquarters
Figure 7.4 mRNA Custom Synthesis Service Providers: Distribution by Company Size and Location of Headquarters
Figure 7.5 mRNA Custom Synthesis Service Providers: Distribution by Type of Service Offered
Figure 7.6 mRNA Custom Synthesis Service Providers: Distribution by Starting Material
Figure 7.7 mRNA Custom Synthesis Service Providers: Distribution by Structural Modification
Figure 7.8 mRNA Custom Synthesis Service Providers: Distribution by Type of Purification Method
Figure 7.9 mRNA Custom Synthesis Service Providers: Distribution by Scale of Operation
Figure 7.10 mRNA Custom Synthesis Service Providers: Distribution by Application Area
Figure 7.11 mRNA Custom Synthesis Service Providers: Distribution by GMP Compliance
Figure 8.1 Company Competitiveness Analysis: Service Providers based in North America
Figure 8.2 Company Competitiveness Analysis: Service Providers based in Europe
Figure 8.3 Company Competitiveness Analysis: Service Providers based in Asia-Pacific
Figure 9.1 mRNA Contract Manufacturing Service Providers: Distribution by Year of Establishment
Figure 9.2 mRNA Contract Manufacturing Service Providers: Distribution by Company Size
Figure 9.3 mRNA Contract Manufacturing Service Providers: Distribution by Location of Headquarters (Region)
Figure 9.4 mRNA Contract Manufacturing Service Providers: Distribution by Location of Headquarters (Country)
Figure 9.5 mRNA Contract Manufacturing Service Providers: Distribution by Location of Manufacturing Facilities
Figure 9.6 mRNA Contract Manufacturing Service Providers: Distribution by Type of Product Manufactured
Figure 9.7 mRNA Contract Manufacturing Service Providers: Distribution by GMP Compliance
Figure 9.8 mRNA Contract Manufacturing Service Providers: Distribution by Scale of Operation
Figure 9.9 mRNA Contract Manufacturing Service Providers: Distribution by Type of Additional Services Offered
Figure 10.1 Company Competitiveness Analysis: Service Providers based in North America
Figure 10.2 Company Competitiveness Analysis: Service Providers based in Europe
Figure 10.3 Company Competitiveness Analysis: Service Providers based in Asia-Pacific
Figure 11.1 mRNA Synthesis Kits: Distribution by Kit Components
Figure 11.2 mRNA Synthesis Kits: Distribution by Type of Enzyme
Figure 11.3 mRNA Synthesis Kits: Distribution by Type of Enzyme Mix Used
Figure 11.4 mRNA Synthesis Kits: Distribution by mRNA Component Modified
Figure 11.5 mRNA Synthesis Kits: Distribution by Number of Reactions
Figure 11.6 mRNA Synthesis Kits: Distribution by Yield Per Reaction
Figure 11.7 mRNA Synthesis Kits: Distribution by Reaction Run Time
Figure 11.8 mRNA Synthesis Kits: Distribution by Shelf Life
Figure 11.9 mRNA Synthesis Kit Providers: Distribution by Year of Establishment
Figure 11.10 mRNA Synthesis Kit Providers: Distribution by Company Size
Figure 11.11 mRNA Synthesis Kit Providers: Distribution by Location of Headquarters
Figure 11.12 Most Active Players: Distribution by Number of Kits Developed
Figure 12.1 mRNA Synthesis Kits: 2D Dot Plot
Figure 13.1 Danaher: Annual Revenues, Since FY 2021 (USD Billion)
Figure 13.2 Thermo Fischer Scientific: Annual Revenues, Since FY 2021 (USD Billion)
Figure 13.3 BioNTech: Annual Revenues, Since FY 2021 (EUR Billion)
Figure 13.4 Eurogentec: Annual Revenues, Since FY 2021 (JPY Billion)
Figure 14.1 Lonza: Annual Revenues, Since FY 2021 (CHF Billion)
Figure 14.2 Merck: Annual Revenues, Since FY 2021 (EUR Billion)
Figure 14.3 Samsung Biologics: Annual Revenues, Since FY 2021 (KRW Trillion)
Figure 14.4 ST Pharm: Annual Revenues, Since FY 2021 (KRW Billion)
Figure 14.5 Wuxi Biologics: Annual Revenues, Since FY 2020 (RMB Billion)
Figure 16.1 Partnerships and Collaborations: Distribution by Year of Partnership
Figure 16.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 16.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 16.4 Partnerships and Collaborations: Distribution by Type of Partner
Figure 16.5 Partnerships and Collaborations: Distribution by Type of Pharmaceutical
Figure 16.6 Partnerships and Collaborations: Distribution by Type of Drug Product
Figure 16.7 Most Active Players: Distribution by Number of Partnerships
Figure 16.8 Partnerships and Collaborations: Local and International Deals
Figure 16.9 Partnerships and Collaborations: Intercontinental and Intracontinental Deals
Figure 18.1 Big Player Initiatives: Distribution by Year of Initiative
Figure 18.2 Big Player Initiatives: Distribution by Type of Initiative
Figure 18.3 Big Player Initiatives: Distribution by Year and Type of Initiative
Figure 18.4 Big Player Initiatives: Distribution of Player by Number of Initiatives
Figure 18.5 Big Player Initiatives: Distribution of Player by Type of Initiative
Figure 18.6 Big Player Initiatives: Distribution by Type of Pharmaceutical
Figure 18.7 Big Player Initiatives: Distribution by Therapeutic Area
Figure 18.8 Big Player Initiatives: Distribution of Player by Number of Partnerships
Figure 18.9 Big Player Initiatives: Distribution by Type of Partnership
Figure 18.10 Big Player Initiatives: Distribution of Player by Number of Expansions
Figure 18.11 Big Player Initiatives: Distribution by Type of Expansion
Figure 18.12 Big Player Initiatives: Distribution of Player by Region of Expansion
Figure 19.1 Market Trends and Outlook: Market Drivers
Figure 19.2 Market Trends and Outlook: Market Restraints
Figure 19.3 Market Trends and Outlook: Market Opportunities
Figure 19.4 Market Trends and Outlook: Market Challenges
Figure 20.1 Global mRNA Synthesis and Manufacturing Market, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Figure 20.2 Global mRNA Synthesis and Manufacturing Market, Forecasted Estimates (till 2035): Conservative Scenario
Figure 20.3 Global mRNA Synthesis and Manufacturing Market, Forecasted Estimates (till 2035): Optimistic Scenario
Figure 21.1 mRNA Synthesis and Manufacturing Market: Distribution by Type of Product
Figure 21.2 mRNA Synthesis and Manufacturing Market for Active Pharmaceutical Ingredients, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Figure 21.3 mRNA Synthesis and Manufacturing Market for Finished Dose Formulations, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Figure 22.1 mRNA Synthesis and Manufacturing Market: Distribution by Scale of Operation
Figure 22.2 mRNA Synthesis and Manufacturing Market for Preclinical and Clinical Scale, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Figure 22.3 mRNA Synthesis and Manufacturing Market for Commercial Scale, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Figure 23.1 mRNA Synthesis and Manufacturing Market: Distribution by Synthesis and Manufacturing Activity
Figure 23.2 mRNA Synthesis and Manufacturing Market for Commercial Manufacturing, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Figure 23.3 mRNA Synthesis and Manufacturing Market for In-house Manufacturing, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Figure 24.1 mRNA Synthesis and Manufacturing Market: Distribution by Type of Indication
Figure 24.2 mRNA Synthesis and Manufacturing Market for COVID Indication, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Figure 24.3 mRNA Synthesis and Manufacturing Market for Non-COVID Indication, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Figure 25.1 mRNA Synthesis and Manufacturing Market: Distribution by Therapeutic Area
Figure 25.2 mRNA Synthesis and Manufacturing Market for Infectious Diseases, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Figure 25.3 mRNA Synthesis and Manufacturing Market for Oncological Diseases, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Figure 25.4 mRNA Synthesis and Manufacturing Market for Other Diseases, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Figure 26.1 mRNA Synthesis and Manufacturing Market: Distribution by Application Area
Figure 26.2 mRNA Synthesis and Manufacturing Market for mRNA Vaccines, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Figure 26.3 mRNA Synthesis and Manufacturing Market for mRNA Therapeutics, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Figure 27.1 mRNA Synthesis and Manufacturing Market: Distribution by Geographical Region
Figure 27.2 mRNA Synthesis and Manufacturing Market in North America, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Figure 27.3 mRNA Synthesis and Manufacturing Market in the US, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Figure 27.4 mRNA Synthesis and Manufacturing Market in Canada, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Figure 27.5 mRNA Synthesis and Manufacturing Market in Europe, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Figure 27.6 mRNA Synthesis and Manufacturing Market in Germany, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Figure 27.7 mRNA Synthesis and Manufacturing Market in France, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Figure 27.8 mRNA Synthesis and Manufacturing Market in the UK, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Figure 27.9 mRNA Synthesis and Manufacturing Market in Italy, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Figure 27.10 mRNA Synthesis and Manufacturing Market in Spain, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Figure 27.11 mRNA Synthesis and Manufacturing Market in rest of Europe, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Figure 27.12 mRNA Synthesis and Manufacturing Market in Asia-Pacific, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Figure 27.13 mRNA Synthesis and Manufacturing Market in China, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Figure 27.14 mRNA Synthesis and Manufacturing Market in India, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Figure 27.15 mRNA Synthesis and Manufacturing Market in Japan, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Figure 27.16 mRNA Synthesis and Manufacturing Market in South Korea, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Figure 27.17 mRNA Synthesis and Manufacturing Market in rest of Asia-Pacific, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Figure 27.18 mRNA Synthesis and Manufacturing Market in Latin America, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Figure 27.19 mRNA Synthesis and Manufacturing Market in Brazil, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Figure 27.20 mRNA Synthesis and Manufacturing Market in Argentina, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Figure 27.21 mRNA Synthesis and Manufacturing Market in Middle East and North Africa, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Figure 27.22 mRNA Synthesis and Manufacturing Market in Saudi Arabia, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Figure 27.23 mRNA Synthesis and Manufacturing Market in Israel, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Figure 27.24 mRNA Synthesis and Manufacturing Market in United Arab Emirates, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Figure 27.25 mRNA Synthesis and Manufacturing Market in rest of Middle East and North Africa, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

LIST OF TABLES

Table 7.1 List of mRNA Custom Synthesis Service Providers
Table 9.1 List of mRNA Contract Manufacturing Service Providers
Table 11.1 List of mRNA Synthesis Kits
Table 11.2 List of mRNA Synthesis Kit Developers
Table 12.1 Aldevron: Service Portfolio
Table 12.2 Aldevron: Recent Developments and Future Outlook
Table 12.3 Thermo Fischer Scientific: Service Portfolio
Table 12.4 Thermo Fischer Scientific: Recent Developments and Future Outlook
Table 12.5 Revolution Biomanufacturing: Service Portfolio
Table 12.6 Revolution Biomanufacturing: Recent Developments and Future Outlook
Table 12.7 BioNTech: Service Portfolio
Table 12.8 BioNTech: Recent Developments and Future Outlook
Table 12.9 Eurogentec: Service Portfolio
Table 12.10 Eurogentec: Recent Developments and Future Outlook
Table 12.11 Biocell: Service Portfolio
Table 12.12 Biocell: Recent Developments and Future Outlook
Table 12.13 YXgene: Service Portfolio
Table 12.14 YXgene: Recent Developments and Future Outlook
Table 13.1 Curia: Service Portfolio
Table 13.2 Curia: Recent Developments and Future Outlook
Table 13.3 Lonza: Service Portfolio
Table 13.4 Lonza: Recent Developments and Future Outlook
Table 13.5 Merck: Service Portfolio
Table 13.6 Merck: Recent Developments and Future Outlook
Table 13.7 Porton Advanced: Service Portfolio
Table 13.8 Porton Advanced: Recent Developments and Future Outlook
Table 13.9 Samsung Biologics: Service Portfolio
Table 13.10 Samsung Biologics: Recent Developments and Future Outlook
Table 13.11 ST Pharm: Service Portfolio
Table 13.12 ST Pharm: Recent Developments and Future Outlook
Table 13.13 Vernal Biosciences: Service Portfolio
Table 13.14 Vernal Biosciences: Recent Developments and Future Outlook
Table 13.15 Wuxi Biologics: Service Portfolio
Table 13.16 Wuxi Biologics: Recent Developments and Future Outlook
Table 14.1 APExBIO: mRNA Synthesis Kits Portfolio
Table 14.2 Biorbyt: mRNA Synthesis Kits Portfolio
Table 14.3 Cell Script: mRNA Synthesis Kits Portfolio
Table 14.4 Creative Biogene: mRNA Synthesis Kits Portfolio
Table 14.5 Jena Bioscience: mRNA Synthesis Kits Portfolio
Table 14.6 Thermo Fischer Scientific: mRNA Synthesis Kits Portfolio
Table 15.1 mRNA Synthesis and Manufacturing: List of Partnerships and Collaborations, since 2019
Table 15.2 mRNA Synthesis and Manufacturing: Information on Location of Headquarters (Country / Region) and Type of Agreement (Intercontinental / Intracontinental)
Table 16.1 mRNA Drug Developers: Potential Strategic Partners in North America
Table 16.2 Most Likely Partner
Table 17.1 Big Player Initiatives: List of mRNA Synthesis and Manufacturing Focused Initiatives, since 2019
Table 35.1 mRNA Custom Synthesis Service Providers: Distribution by Year of Establishment
Table 35.2 mRNA Custom Synthesis Service Providers: Distribution by Company Size
Table 35.3 mRNA Custom Synthesis Service Providers: Distribution by Location of Headquarters
Table 35.4 mRNA Custom Synthesis Service Providers: Distribution by Company Size and Location of Headquarters
Table 35.5 mRNA Custom Synthesis Service Providers: Distribution by Type of Service Offered
Table 35.6 mRNA Custom Synthesis Service Providers: Distribution by Starting Material
Table 35.7 mRNA Custom Synthesis Service Providers: Distribution by Structural Modification
Table 35.8 mRNA Custom Synthesis Service Providers: Distribution by Type of Purification Method
Table 35.9 mRNA Custom Synthesis Service Providers: Distribution by Scale of Operation
Table 35.10 mRNA Custom Synthesis Service Providers: Distribution by Application Area
Table 35.11 mRNA Custom Synthesis Service Providers: Distribution by GMP Compliance
Table 35.12 mRNA Contract Manufacturing Service Providers: Distribution by Year of Establishment
Table 35.13 mRNA Contract Manufacturing Service Providers: Distribution by Company Size
Table 35.14 mRNA Contract Manufacturing Service Providers: Distribution by Location of Headquarters (Region)
Table 35.15 mRNA Contract Manufacturing Service Providers: Distribution by Location of Headquarters (Country)
Table 35.16 mRNA Contract Manufacturing Service Providers: Distribution by Location of Manufacturing Facilities
Table 35.17 mRNA Contract Manufacturing Service Providers: Distribution by Type of Product Manufactured
Table 35.18 mRNA Contract Manufacturing Service Providers: Distribution by GMP Compliance
Table 35.19 mRNA Contract Manufacturing Service Providers: Distribution by Scale of Operation
Table 35.20 mRNA Contract Manufacturing Service Providers: Distribution by Type of Additional Services Offered
Table 35.21 mRNA Synthesis Kits: Distribution by Kit Components
Table 35.22 mRNA Synthesis Kits: Distribution by Type of Enzyme
Table 35.23 mRNA Synthesis Kits: Distribution by Type of Enzyme Mix Used
Table 35.24 mRNA Synthesis Kits: Distribution by mRNA Component Modified
Table 35.25 mRNA Synthesis Kits: Distribution by Number of Reactions
Table 35.26 mRNA Synthesis Kits: Distribution by Yield Per Reaction
Table 35.27 mRNA Synthesis Kits: Distribution by Reaction Run Time
Table 35.28 mRNA Synthesis Kits: Distribution by Shelf Life
Table 35.29 mRNA Synthesis Kit Providers: Distribution by Year of Establishment
Table 35.30 mRNA Synthesis Kit Providers: Distribution by Company Size
Table 35.31 mRNA Synthesis Kit Providers: Distribution by Location of Headquarters
Table 35.32 Most Active Players: Distribution by Number of Kits Developed
Table 35.33 Danaher: Annual Revenues, Since FY 2021 (USD Billion)
Table 35.34 Thermo Fischer Scientific: Annual Revenues, Since FY 2021 (USD Billion)
Table 35.35 BioNTech: Annual Revenues, Since FY 2021 (EUR Billion)
Table 35.36 Kaneka: Annual Revenues, Since FY 2021 (JPY Billion)
Table 35.37 Lonza: Annual Revenues, Since FY 2021 (CHF Billion)
Table 35.38 Merck: Annual Revenues, Since FY 2021 (EUR Billion)
Table 35.39 Samsung Biologics: Annual Revenues, Since FY 2021 (KRW Trillion)
Table 35.40 ST Pharm: Annual Revenues, Since FY 2021 (KRW Billion)
Table 35.41 Wuxi Biologics: Annual Revenues, Since FY 2020 (RMB Billion)
Table 35.42 Partnerships and Collaborations: Distribution by Year of Partnership
Table 35.43 Partnerships and Collaborations: Distribution by Type of Partnership
Table 35.44 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Table 35.45 Partnerships and Collaborations: Distribution by Type of Partner
Table 35.46 Partnerships and Collaborations: Distribution by Type of Pharmaceutical
Table 35.47 Partnerships and Collaborations: Distribution by Type of Drug Product
Table 35.48 Most Active Players: Distribution by Number of Partnerships
Table 35.49 Partnerships and Collaborations: Local and International Deals
Table 35.50 Partnerships and Collaborations: Intercontinental and Intracontinental Deals
Table 35.51 Big Player Initiatives: Distribution by Year of Initiative
Table 35.52 Big Player Initiatives: Distribution by Type of Initiative
Table 35.53 Big Player Initiatives: Distribution by Year and Type of Initiative
Table 35.54 Big Player Initiatives: Distribution of Player by Number of Initiatives
Table 35.55 Big Player Initiatives: Distribution of Player by Type of Initiative
Table 35.56 Big Player Initiatives: Distribution by Type of Pharmaceutical
Table 35.57 Big Player Initiatives: Distribution by Therapeutic Area
Table 35.58 Big Player Initiatives: Distribution of Player by Number of Partnerships
Table 35.59 Big Player Initiatives: Distribution by Type of Partnership
Table 35.60 Big Player Initiatives: Distribution of Player by Number of Expansions
Table 35.61 Big Player Initiatives: Distribution by Type of Expansion
Table 35.62 Big Player Initiatives: Distribution of Player by Region of Expansion
Table 35.63 Global mRNA Synthesis and Manufacturing Market, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Table 35.64 Global mRNA Synthesis and Manufacturing Market, Forecasted Estimates (till 2035): Conservative Scenario
Table 35.65 Global mRNA Synthesis and Manufacturing Market, Forecasted Estimates (till 2035): Optimistic Scenario
Table 35.66 mRNA Synthesis and Manufacturing Market: Distribution by Type of Product
Table 35.67 mRNA Synthesis and Manufacturing Market for Active Pharmaceutical Ingredients, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Table 35.68 mRNA Synthesis and Manufacturing Market for Finished Dose Formulations, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Table 35.69 mRNA Synthesis and Manufacturing Market: Distribution by Scale of Operation
Table 35.70 mRNA Synthesis and Manufacturing Market for Preclinical and Clinical Scale, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Table 35.71 mRNA Synthesis and Manufacturing Market for Commercial Scale, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Table 35.72 mRNA Synthesis and Manufacturing Market: Distribution by Synthesis and Manufacturing Activity
Table 35.73 mRNA Synthesis and Manufacturing Market for Commercial Manufacturing, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Table 35.74 mRNA Synthesis and Manufacturing Market for In-house Manufacturing, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Table 35.75 mRNA Synthesis and Manufacturing Market: Distribution by Type of Indication
Table 35.76 mRNA Synthesis and Manufacturing Market for COVID Indication, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Table 35.77 mRNA Synthesis and Manufacturing Market for Non-COVID Indication, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Table 35.78 mRNA Synthesis and Manufacturing Market: Distribution by Therapeutic Area
Table 35.79 mRNA Synthesis and Manufacturing Market for Infectious Diseases, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Table 35.80 mRNA Synthesis and Manufacturing Market for Oncological Diseases, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Table 35.81 mRNA Synthesis and Manufacturing Market for Other Diseases, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Table 35.82 mRNA Synthesis and Manufacturing Market: Distribution by Application Area
Table 35.83 mRNA Synthesis and Manufacturing Market for mRNA Vaccines, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Table 35.84 mRNA Synthesis and Manufacturing Market for mRNA Therapeutics, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Table 35.85 mRNA Synthesis and Manufacturing Market: Distribution by Geographical Region
Table 35.86 mRNA Synthesis and Manufacturing Market in North America, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Table 35.87 mRNA Synthesis and Manufacturing Market in the US, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Table 35.88 mRNA Synthesis and Manufacturing Market in Canada, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Table 35.89 mRNA Synthesis and Manufacturing Market in Europe, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Table 35.90 mRNA Synthesis and Manufacturing Market in Germany, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Table 35.91 mRNA Synthesis and Manufacturing Market in France, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Table 35.92 mRNA Synthesis and Manufacturing Market in the UK, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Table 35.93 mRNA Synthesis and Manufacturing Market in Italy, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Table 35.94 mRNA Synthesis and Manufacturing Market in Spain, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Table 35.95 mRNA Synthesis and Manufacturing Market in rest of Europe, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Table 35.96 mRNA Synthesis and Manufacturing Market in Asia-Pacific, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Table 35.97 mRNA Synthesis and Manufacturing Market in China, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Table 35.98 mRNA Synthesis and Manufacturing Market in India, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Table 35.99 mRNA Synthesis and Manufacturing Market in Japan, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Table 35.100 mRNA Synthesis and Manufacturing Market in South Korea, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Table 35.101 mRNA Synthesis and Manufacturing Market in rest of Asia-Pacific, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Table 35.102 mRNA Synthesis and Manufacturing Market in Latin America, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Table 35.103 mRNA Synthesis and Manufacturing Market in Brazil, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Table 35.104 mRNA Synthesis and Manufacturing Market in Argentina, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Table 35.105 mRNA Synthesis and Manufacturing Market in Middle East and North Africa, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Table 35.106 mRNA Synthesis and Manufacturing Market in Saudi Arabia, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Table 35.107 mRNA Synthesis and Manufacturing Market in Israel, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Table 35.108 mRNA Synthesis and Manufacturing Market in United Arab Emirates, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Table 35.109 mRNA Synthesis and Manufacturing Market in rest of Middle East and North Africa, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

Aldevron
Aurigene Pharmaceutical Services
Biomay
Curia
eTheRNA
Eurogentec
Genscript
Merck KGaA
TriLink BioTechnologies
Vernal Biosciences
WuXi Biologics
APExBIO
CELLSCRIPT
Enzynomics
Jena Bioscience
New England Biolabs
Thermo Fisher Scientific

Methodology

LOADING...

License	Format	Properties	Price
SINGLE USER LICENSE PDF and Excel	The electronic report will be emailed to you. The file formats are PDF and Excel.	This is a single user license, allowing one user access to the product.	€4270EUR$4,799USD£3,759GBP
SITE LICENSE PDF and Excel	The electronic report will be emailed to you. The file formats are PDF and Excel.	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€6228EUR$6,999USD£5,482GBP
ENTERPRISE LICENSE PDF and Excel	The electronic report will be emailed to you. The file formats are PDF and Excel.	This is an enterprise license, allowing all employees within your organization access to the product.	€16017EUR$17,999USD£14,099GBP

mRNA Synthesis and Manufacturing Market: Growth and Trends

mRNA Synthesis and Manufacturing Market: Key Insights

Report Segmentation

mRNA Synthesis and Manufacturing Market: Key Segments

Drug Substances (APIs) are Likely to Dominate the mRNA Synthesis and Manufacturing Market During the Forecast Period

mRNA Therapeutics is the Fastest Growing Segment in the mRNA Synthesis and Manufacturing Market During the Forecast Period

Infectious Diseases Segment Accounts for the Largest Share for the mRNA Synthesis and Manufacturing Market

North America Holds the Largest Share of the Market

Sample Players in the mRNA Synthesis and Manufacturing Market, Profiled in the Report Include:

Primary Research Overview

mRNA Synthesis and Manufacturing Market: Research Coverage

Key Questions Answered in this Report

Reasons to Buy this Report

Additional Benefits

Table of Contents

Companies Mentioned (Partial List)

Methodology

Related Topics

Related Reports

mRNA Synthesis & Manufacturing Market - Global Forecast 2025-2030

Messenger Ribonucleic Acid (mRNA) Synthesis and Manufacturing Market Report 2025

mRNA Synthesis Raw Materials - Global Strategic Business Report

mRNA Therapeutics CDMO Market Report 2025

MRNA Synthesis & Manufacturing Market by Product (Consumables [Transcription, Purification, Analysis & Characterization], Instrument), Service (Synthesis, Purification, Manufacturing & Scale-Up), Application (CGT, Vaccines) - Global Forecast to 2029